Clinical trials: Nutrition Labeling, active
Overweight and Obesity
An Open Label 100 Person Study Evaluating a Natural Supplement for Weight Loss and Fat Loss.
The goal of this clinical trial is to learn if motus, a natural supplement can support healthy weight loss and fat loss in a real world setting without caloric restrictions or exercise requirements.
- Trial name
- NCT07152470
- Testing
- Diet and Exercise Tracking
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Prostasis, LLC, dba Tonum Health
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Malnutrition, Child
Community-based, Controlled, Open-label, Cluster-randomized Trial for the Reduction of Chronic Malnutrition in Children Under Two Years of Age, With Three Intervention Arms Grouped by Clusters, in Two Provinces in Southern Angola, Huíla and Cunene.
The severity of the stunting in the provinces of Huíla and Cunene, Angola, in children aged 6 to 59 months is considered to be very high, as defined by the World Health Organization (WHO) classification of 2018.
- Trial name
- NCT05571280
- Testing
- Nutritional Supplementation, Money transfers, Standard intervention
- Where
- 2 sites in Angola
- Volunteers
- 1,423 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Obesity & Overweight
ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
This randomized controlled trial aims to evaluate the efficacy and safety of Endoscopic Radial Compression Gastroplasty (ERCG) in mitigating weight regain following discontinuation of glucagon-like peptide-1 receptor agonists…
- Trial name
- NCT07908823
- Testing
- Endoscopic Radial Compression Gastroplasty (ERCG), Intensive Lifestyle Intervention (ILI)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
End Stage Renal Disease (ESRD)
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
This is a multicenter, randomized, parallel controlled Phase IV clinical study to evaluate the safety and efficacy of amino acid (15) peritoneal dialysis solution in patients undergoing peritoneal dialysis with malnutrition in…
- Trial name
- NCT06597201
- Testing
- amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution
- Where
- 21 sites in China
- Volunteers
- 400 people
- Sponsor
- Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.
- Trial name
- NCT06366464
- Testing
- Pitolisant tablet
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Harmony Biosciences Management, Inc.
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atypical Endometrial Hyperplasia, Fertility Issues
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.
- Conditions
- Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity
- Trial name
- NCT05316493
- Testing
- Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Xiaojun Chen
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Atrial Fibrillation, Obesity & Overweight
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to…
- Conditions
- Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
- Trial name
- TEAR-AF (NCT07715929)
- Testing
- Tirzepatide, Structured Lifestyle Intervention
- Volunteers
- 710 people
- Sponsor
- Yunlong Wang
Obesity & Overweight
A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
The goal of this clinical trial is to determine whether a semaglutide dose-tapering regimen is non-inferior to a treatment-dose maintenance regimen for weight-loss maintenance in adults with overweight or obesity who have…
- Trial name
- NCT07783854
- Testing
- Semaglutide Dose-Tapering Regimen, Semaglutide Maintenance-Dose Regimen
- Volunteers
- 72 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Childhood Obesity
Time Restricted Eating in Childhood Obesity (TRECO)
The goal of this clinical trial is to learn if time-restricted eating (TRE), an alternative method of reducing energy intake which has gained popularity in recent years, works to treat obesity in children.
- Trial name
- TRECO (NCT06583447)
- Testing
- Calorie-restricted diet (CRD), Time-restricted eating (TRE)
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Xiaoyan Shi
Obesity
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
- Trial name
- NCT07285902
- Testing
- HRS9531 injection, Semaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 572 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
X-linked Hypophosphatemia
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
- Trial name
- NCT06525636
- Testing
- KK8123
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 39 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Fatty Liver, Overweight/Obesity
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases.
- Conditions
- Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
- Trial name
- Test2Func (NCT03851627)
- Testing
- Testosterone Undecanoate
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Alexandra Kautzky-Willer
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight.
- Trial name
- NCT07808060
- Testing
- Eloralintide, Combined oral contraceptive
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company